Michael Michelson - Zimmer Biomet Independent Director
| ZBH Stock | USD 121.52 0.74 0.61% |
Director
Mr. Michael W. Michelson is Independent Directorof the Company. Mr. Michelson served as Senior Advisory Partner, KKR Management LLC, a private equity investment manager and the general partner of KKR Co. L.P., since January 2018. Previously, Member, KKR Management LLC since October 2009. Before that, Mr. Michelson was a member of the limited liability company that served as the general partner of Kohlberg Kravis Roberts Co. L.P. since 1996. He joined KKR in 1981 since 2015.
| Age | 69 |
| Tenure | 9 years |
| Address | 345 East Main Street, Warsaw, IN, United States, 46580 |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Zimmer Biomet's Fixed Asset Turnover is decreasing as compared to previous years. The Zimmer Biomet's current Asset Turnover is estimated to increase to 0.68, while Total Assets are projected to decrease to under 13.7 B.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| William Coffin | Bone Biologics Corp | 69 | |
| Jimmy Delshad | Bone Biologics Corp | 74 | |
| Bret Hankey | Bone Biologics Corp | 39 | |
| Chia Soo | Bone Biologics Corp | 47 | |
| Benjamin Wu | Bone Biologics Corp | 53 | |
| John Booth | Bone Biologics Corp | 60 | |
Management Performance
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Coleman Lannum, Senior Vice President - Investor Relations | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Matt Abernethy, CPA, Vice President Investor Relations | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Daniel Florin, CFO, Senior Vice President | ||
| Robert Marshall, Vice President - Investor Relations, Treasurer | ||
| David Nolan, Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing | ||
| Joseph Cucolo, President Americas | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Cecil Pickett, Independent Director | ||
| Angela Main, Global VP | ||
| Aure Bruneau, Group President Spine, CMF, Thoracic and Surgery Assisting Technology | ||
| Jeffrey Rhodes, Director | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Katarzyna MazurHofsaess, President Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Paul Bisaro, Independent Director | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Adam Johnson, Group President Spine, Dental, CMF and Thoracic | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Daniel Williamson, Group President Joint Reconstruction | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| David Dvorak, CEO and President and Director | ||
| Michael Farrell, Independent Director | ||
| Tony Collins, Chief Accounting Officer, Vice President Controller | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| Gail Boudreaux, Independent Director | ||
| Stuart Kleopfer, President Americas | ||
| Robert Hagemann, Independent Director | ||
| Robert Delps, President Americas |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 30.72 B | ||||
| Shares Outstanding | 205.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 90.90 % | ||||
| Number Of Shares Shorted | 4.73 M | ||||
| Price To Earning | 77.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.96 | Earnings Share 4.89 | Revenue Per Share 35.43 | Quarterly Revenue Growth 0.063 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.